People With Type 2 Diabetes Have a Greater Risk of Cardiovascular Disease Even With Risk Factors Optimally Controlled
December 02, 2020 02:30pm
Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood neurobehavioral disorder in the United States, with about 9.4% of children aged 2 to 17 years having received a diagnosis. The prevalence increased by 57% from 2007-2008 to 2011-2012, according to the results of a recent study.
Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood neurobehavioral disorder in the United States,1with about 9.4% of children aged 2 to 17 years having received a diagnosis, according to the CDC.2
ADHD prevalence increased by 57% from 2007-2008 to 2011-2012, according to the results of a recent study in theJournal of Developmental & Behavioral Pediatrics.3ADHD left untreated can negatively affect patients both academically and socially. Primary care providers (PCPs) should take note of this astounding increase in prevalence and aid with early recognition of symptoms to provide a concise management plan for these patients.
ADHD is marked by 3 key behaviors: hyperactivity, impulsivity, and inattention.4,5
Hyperactivity is when a patient moves about constantly, including in situations when it is not appropriate. A patient may even excessively fidget, talk, or tap. For preschool-aged children, hyperactivity is the most common symptom of ADHD.
Impulsivity in patients may cause them to act in the moment without first thinking. This may have a potential for harm. A patient with impulsivity may have a desire for instant gratification. Sometimes an impulsive patient may make important decisions without considering the long-term consequences or interrupt others.5
Inattention can mean that the patient is disorganized, has difficulty sustaining focus, lacks persistence, and wanders off task. In elementary grades, patients may be described as lazy.6In young children with ADHD, hyperactivity and impulsivity are the most prevalent presenting behaviors. TheDiagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5) criteria can support PCPs in making a diagnosis of ADHD. Diagnosis can be made using only these DSM-5 criteria, based on patients’ exhibiting a persistent pattern of inattention and/or hyperactivity/impulsivity that interferes with development and functioning.2,7Management can be determined by referencing the American Academy of Pediatrics (AAP) clinical practice guideline for ADHD, which provides detailed, evidence-based information regarding managing patients aged 4 to 18 years and treatment recommendations.1,8
Experts are unsure of what causes ADHD but have concluded that many factors should be considered, such as brain injuries, cigarette smoking and/ or drug use during pregnancy, exposure to environmental toxins, genes, and low birth weight.5Study results have shown that ADHD is diagnosed more in men than in women. In addition, non-Latino white patients have a higher prevalence of ADHD than other ethnic and racial groups. Most patients receive a diagnosis between 3 and 6 years of age, with a median age of onset at 6 years old.5
Children with ADHD symptoms should be comprehensively evaluated as early as 4 years old by a licensed pediatrician, psychiatrist, or psychologist with expertise in the condition. Professionals should gather information from at least 2 different environments (home and school) and perform a comprehensive developmental, educational, family, and medical history.6
ADHD can be successfully managed with the appropriate plan provided by the PCP. ADHD management consists of behavioral therapy (BT) and medications. For children older than 6 years, the AAP recommends BT and medication as part of the management plan. In children younger than 6 years, BT is indicated as the first line of treatment.2BT is a treatment option that can reduce the behaviors prominent in patients with ADHD.
There are 2 types of BT: BT with children and parent training in BT. Having a child with disruptive behaviors can create stress for the entire family.7The child—parent relationship is affected by ADHD because of the disruptive behaviors. It is important for not only the child to be involved in BT but the parents as well.
In BT with children, the therapist helps the child convey improved behaviors to replace unfavorable behaviors.2In parent training in BT, parents learn skills to guide and teach their children to better control their behavior.2
Four programs for parents of young children with ADHD that have been shown to significantly help behavior and symptoms include the Forest Parenting Programme, the Incredible Years parenting programs, the Parent-Child Interaction Therapy, and the Triple P (Positive Parenting Program).2Medications can be used in combination with BT or initiated alone in children older than 6 years. ADHD medications include stimulants and nonstimulant medications.
Stimulants are the first-line treatment for ADHD, with 75% to 90% of children taking them.4Stimulants improve focus because they increase dopamine and norepinephrine, which play an essential role in attention and thinking. Stimulants commonly prescribed include dexmethylphenidate (Focalin), dextroamphetamine (Dexedrine, Dextrostat, ProCentra, and Zenzedi), dextroamphetamine/amphetamine (Adderall), methamphetamine (Desoxyn), and methylphenidate (Methylin and Ritalin). Methylphenidate (Ritalin) is the cheapest stimulant medication, costing about $33.55 for 60 days’ worth of 5-mg tablets. Dextroamphetamine/ amphetamine (Adderall) is approved by the FDA for children 3 years and older.4Stimulants come in several different preparations (short acting, intermediate acting, and long acting) to treat ADHD. There are no clear benefits of one preparation over another. The choice depends on how the child responds to each individually.
Nonstimulants take longer to work than stimulants. They can be effective when used alone or in combination with a stimulant. PCPs may prescribe a nonstimulant because of possible adverse effects or contraindications of stimulants or use one in combination with a stimulant for increased effectiveness. Nonstimulants include atomoxetine (Strattera), clonidine extended release (Kapvay), and guanfacine (Intuniv).2,4PCPs must determine what is best for the patient: BT, medication, or both.
PCPs provide a fundamental role in assessing key behaviors to lead to a diagnosis of ADHD. Through early recognition of these behaviors, PCPs can provide appropriate management for children with BT and/or medications. Ultimately, the goal of management is to improve these behaviors to help children progress academically, developmentally, and socially.